Depending on the BP cutoff definition (140/90 or 130/90), hypertension (HTN) affects 30 to 46% of the world population. Based on attributable risk, it causes 18% of the heart attacks, 35% of the strokes, 39% of heart failure in men and 59% of heart failure in women, and 23% of renal failure. It contributes to over 500,000 deaths each year from cardiovascular disease. It costs over $118 billion/year in related cardiovascular disease. The average cost is $1,920 per hypertensive per year and that is expected to triple in the next 10 years. It is the #2 office visit, consuming over 36 million office visits per year.
Despite its high prevalence, significant morbidity and mortality, and excessive cost, it is poorly managed. Less than half are controlled. A pilot study of the A4M system completed in 2019 showed a 75% reduction in provider management time an improvement of the blood pressure rate of control from zero to 58% in patients with documented resistant hypertension and 76% in all uncontrolled hypertensives.
You are paying 25% too much for white coat hypertension, missing 20% of your patients that have masked hypertension and getting too little control from a trial-and-error system that delivers inferior results. The ROI for payers using the A4M CDST system is over 10:1. The reduced provider management time more than pays for the system initially and that increases over time from the CV disease risk reduction. Let us show you....
We are looking for early adopters to participate in a pilot study of 420 and up to 2,000 patients. The minimum support fee is $20,000 per month for six months. This includes video seminars, in person seminars, grand rounds, and educational materials on how to manage hypertension and how to use the software. If we do not improve your rate of control over your office-based baseline rate of control, we will refund all fees. It is a no risk proposition.